Thrombotic Microangiopathy Following Chemotherapy with S-1 and Cisplatin in a Patient with Gastric Cancer: A Case Report

Non-Malignant Blood Disorders

Maintenance rituximab for relapsing thrombotic thrombocytopenic purpura: a case report

Transfusion.

Saleem R, Rogers ZR, Neunert C, George JN

doi: 10.1111/trf.15093.

Head and Neck Cancer

Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma

Oncotarget.

Ock CY, Kim S, Keam B, Kim S, Ahn YO, Chung EJ, Kim JH, Kim TM, Kwon SK, Jeon YK, Jung KC, Kim DW, Wu HG, Sung MW, Heo DS

doi: 10.18632/oncotarget.18542.

Lymphoma

Hodgkin’s Lymphoma after Autologous Stem-Cell Transplantation: Effective Consolidation with Brentuximab Vedotin

healthbook Times Oncology Hematology

Schmidt A

doi: 10.36000/hbT.OH.2020.06.025

Lung, Respiratory and Thoracic CancerFurther Publications

Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

healthbook TIMES Oncology Hematology

Astaras C, Bettini A, Betticher D.C

doi: 10.36000/hbT.OH.2020.03.01

Further Publications

Severe, persistent neurotoxicity after transplant-associated thrombotic microangiopathy in a pediatric patient despite treatment with eculizumab

Pediatr Transplant.

Schoettler M, Duncan C, Lehmann L

doi: 10.1111/petr.13381.

Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade

J Immunother Cancer.

Läubli H, Hench J, Stanczak M, Heijnen I, Papachristofilou A, Frank S, Zippelius A, Stenner-Liewen F

doi: 10.1186/s40425-017-0249-y.

SPECIAL REPORT

Further Publications

Cas clinique d’un patient atteint de myélome multiple

Lymphoma

CD19-Directed CAR T Cells Treatment in a Patient With Refractory DLBCL and CNS Involvement

healthbook TIMS Oncology Hematology

Ring A, Müller A

doi: 10.36000/hbT.OH.2019.01.005

Gastrointestinal Cancer

Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line

Case Rep Oncol.

Akhoundova Sanoyan D, Reiner CS, Papageorgiou P, Siebenhüner AR

doi: 10.1159/000504471.

Related content